下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBestatinCat. No.: HY-B0134CAS No.: 58970-76-6Synonyms: Ubenimex分式: CHNO分量: 308.37作靶點(diǎn): Aminopeptidase作通路: Metabolic Enzyme/Protease儲(chǔ)存式: 4C, sealed storage, away from moisture* In solvent : -80C, 6 months; -20C, 1 month (sealedsto
2、rage, away from moisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 8.33 mg/mL (27.01 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 3.2429 mL 16.2143 mL 32.4286 mL5 mM 0.6486 mL 3.2429 mL 6.4857 mL10 mM 0.3243 mL 1.6214 mL 3.2429 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙?/p>
3、案,配制前請(qǐng)先配制澄清的儲(chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.83 mg/mL (2.69 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.83 mg/mL (2.69 mM); Clear solu
4、tion3. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 0.83 mg/mL (2.69 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Bestatin種天然,譜,競(jìng)爭(zhēng)性的氨肽酶抑制劑。體外研究 Bestatin enhances ATRA-induced differentiation and inhibits ATRA-driven phosphorylation of p38 MAPK inATRA-sens
5、itive APL NB4 cells. Bestatin can not reverse the differentiation block in ATRA-resistant APL MR2cells. CD13 ligation with anti-CD13 antibody WM-15 results in phosphorylation of p38 MAPK, reduces theinhibition of Bestatin on the phosphorylation of p38 MAPK, and completely abolishes the enhancement o
6、fBestatin on ATRA-inducing differentiation in NB4 cells 2. Bestatin (600 M)-treated cells progress slowerthrough the cell cycle due to decreased rate of cell growth and the frequency of cell division. Bestatin inhibitsthe frequency of mitosis and the inherent multinuclearity in D. discoideum, and is
7、 not cytotoxic to D.discoideum cells at 0-600 M. Bestatin inhibits aminopeptidase activity in lysates of PsaA-GFP- and GFP-expressing cells by 69.39% 10.5% and 39.93% 18.7% of control, respectively 4.體內(nèi)研究 Bestatin (20 M) significantly reduces CD13 expression in diabetic mice and results a significan
8、t inhibition ofMMP-9 specific gelationolytic band densities compared to diabetic vehicle-treated mice. Bestatin treatmentsignificantly inhibits the expression of VEGF and heparanase in diabetic mice. Intravitreal bestatin treatmentsignificantly downregulates the expression of both HIF-1 and VEGF in
9、diabetic mice retinas. Furthermore,the upregulated expression of heparanase in diabetic mice retinas is significantly inhibited by intravitrealbestatin treatment 1. Bestatin (10, 1, and 0.1mg/kg, i.p.) treatment before the antigen-potentiated humoralresponse to SRBC results in an increased number of
10、 splenocytes producing hemolytic anti-SRBC antibodies(PFC) and the 2-ME-resistant serum hemagglutinin titer (at a dose of 0.1 mg/kg). Bestatin (1 and 0.1 mg/kg)administered to mice five times on alternate days after cyclophosphamide injection does not change thesuppressive effect of the drug regardi
11、ng the number of PFC, and even causes the further decrease of thetotal anti-SRBC hemagglutinins at dose of 1 mg/kg on day 7 after antigen stimulation 3.PROTOCOLKinase Assay 4 Cells are harvested, washed, and lysed in NP-40 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5%NP-40). Total cell prot
12、ein is quantified using the Bradford assay and 1-mg/mL protein aliquots are made. Tenmicroliters of total cell protein is mixed with 290 L of substrate solution (0.1 mg/mL dithiothreitol DTT, 0.1mg/mL albumin, and 1 mM alanine-naphthylamide). Fluorometric measurements (340 nm excitation, 400nm emiss
13、ion) are made after 15 and 30 min. The slope of the line between the 15- and 30-minmeasurements is used to represent aminopeptidase activity. Total cell protein is preincubated with bestatin,amastatin, puromycin, EDTA, and/or ZnCl2 for 20 min before the fluorometric aminopeptidase assay.MCE has not
14、independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 4 Growing cells (1106 to 2106 cells/mL) are diluted to 1.0103 cells/mL and transferred (3 mL) into a well ina 12-well multiwell plate (2.5-cm diameter/well). Cells are treated with 0, 10, 50, 100, 300, or 6
15、00 M Bestatinand allowed to grow at 21C shaking at 180 rpm for 48 h. A hemocytometer is used to measure cell densityafter 0, 24, and 48 h.MCE has not independently confirmed the accuracy of these methods. They are for reference only.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEAnimal Bestatin is
16、 dissolved in PBS. The agent (doses of 10, 1, and 0.1 mg/kg) is injected i.p. to non-Administration 3 cyclophosphamide-treated mice, 5 or 10 times at 24-h intervals before SRBC immunization. The mice areimmunized 24 h after the last dose of bestatin. Pharmacological immunosuppression is induced by a
17、 singleintraperitoneal injection of cyclophosphamide administered at a dose of 350 mg/kg, 12 days before SRBCimmunization. Bestatin at the doses of 1 and 0.1 mg/kg is injected to cyclophosphamide-immunosuppressedmice i.p. five times at 48-h intervals or 10 times at 24-h intervals before SRBC immuniz
18、ation. The first dose ofbestatin is administered 24 h after cyclophosphamide, while the last dose of the drug is injected 24h beforeSRBC immunization.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) J Med Chem. 2017 Mar 9;60(5):1817-1828. Int
19、 J Oncol. 2019 May.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Hossain A, et al. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice. Exp Eye Res. 2016 Aug;149:100-62. Qian X, et al. Inhibition of p38 MAPK Phosphorylation Is Critical for Bestatin to Enhance ATRA-Induced Cell Differentiation in Acu
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 青少年安全自護(hù)國(guó)旗下演講稿模板5篇
- 海洋環(huán)境監(jiān)測(cè)無人艇系統(tǒng)可行性分析報(bào)告
- 蘋果商品化處理生產(chǎn)線新建項(xiàng)目可行性研究報(bào)告
- 鉛酸蓄電池技改項(xiàng)目可行性報(bào)告
- 如何寫一封色差地磚協(xié)議書范文
- 秋天真美麗教案中班
- 山西焦煤買賣合同
- 科技園區(qū)施工合同爭(zhēng)議處理樣本
- 項(xiàng)目年度總結(jié)5篇范文
- 棒球器材租賃合同模板
- 中考數(shù)學(xué)復(fù)習(xí)微專題:有理數(shù)運(yùn)算中的錯(cuò)解及對(duì)策
- DB11-972-2013保險(xiǎn)營(yíng)業(yè)場(chǎng)所風(fēng)險(xiǎn)等級(jí)與安全防范要求
- 高中政治部編版教材高考雙向細(xì)目表
- 輪扣式模板支撐架安全專項(xiàng)施工方案
- 酒店裝飾裝修工程驗(yàn)收表
- 中國(guó)行業(yè)分類代碼表
- 社會(huì)組織協(xié)會(huì)換屆選舉會(huì)議主持詞
- 呼吸科(呼吸與危重癥醫(yī)學(xué)科)出科理論試題及答案
- 清新個(gè)人工作述職報(bào)告PPT模板
- 公路工程通用(專用)合同條款匯編.
- 工程施工現(xiàn)場(chǎng)及常用對(duì)話場(chǎng)景英語集錦
評(píng)論
0/150
提交評(píng)論